// App-Quantinova.ai

563 : A phase I study of continuous (Con) and intermittent (Int) AZD2014 plus fulvestrant (F) in patients (pts) with estrogen receptor (ER+) metastatic breast cancer (BC).

Researchers

Presenter

  • Erika Paige Hamilton

Principal Investigators

  • Manish R. Patel

  • W Larry Gluck

  • Amy M. Weise

  • Shubham Pant

  • Suzanne Fields Jones

  • Patricia Lo Russo

  • Muaiad Kittaneh

  • Sabina Cosulich

  • Elizabeth A. Harrington

  • Gillian Littlewood

  • Elisabeth Maria Oelmann

  • Howard A. Burris

Medical Centers

  • Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN

  • Florida Cancer Specialists and Research Institute, Sarasota, FL

  • Greenville Health System, Greenville, SC

  • Karmanos Cancer Institute, Detroit, MI

  • Oklahoma University Medical Center, Oklahoma City, OK

  • Sarah Cannon Research Institute, Nashville, TN

  • Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • N/A

Drug/Treatment

  • Fulvestrant

  • AZD-2014

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • NCT01597388

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved